NHLBI's BA23 in WHI

This substudy phs001335 Integrative genomics and risk of CHD and related phenotypes in WHI study was to analyze epigenetic markers in blood and to associate these markers with phenotypes related to coronary heart disease. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page [phs000200](./study.cgi?study_id=phs000200) WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study [phs000200](./study.cgi?study_id=phs000200).

In 2013, three contracts were awarded in response to the federal contract opportunity entitled "Towards Maximizing the Scientific Return on the Women's Health Initiative Biological Resource" (NHLBI-CSB-WH-13-01-ST) for research and development in the physical, engineering, and life sciences (except biotechnology) at National Institutes of Health National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD. Supporting documentation for this RFP and a list of contract winners can be found here [https://govtribe.com/project/towards-maximizing-the-scientific-return-on-the-womens-health-initiative-biological-resource-1](https://govtribe.com/project/towards-maximizing-the-scientific-return-on-the-womens-health-initiative-biological-resource-1)

The focus of this contract (HHSN268201300006C) entitled "Integrative genomics for risk of CHD and related phenotypes in the Women's Health Initiative" and awarded to Stanford University was to apply validated high throughput genomic procedures developed by Applied Biosystems and Illumina to the plasma and DNA samples of a subset of WHI participants with existing GWAS and CVD biomarker data. The study funded by this contract is also known as BA23 (the 23rd Broad Agency contract awarded to the WHI study). The original aims of this proposal was to generate these data to allow the BA23 investigators and others 1) to identify genomic biomarkers of CHD events, 2) to integrate these biomarkers into diagnostic and prognostic predictors of CHD and related phenotypes, 3) to elucidate the biology of CHD and related phenotypes, 4) to test whether aging related CpGs mediate the risk of age on CHD, and 5) to revisit the GWAS studies of CHD using new SNP set analysis informed by these new genomic data to uncover novel SNPs, genes, and pathways involved in CHD as well as novel molecularly refined CHD sub phenotypes.